NEJM January 22,2026:Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
NEJM January 22,2026:Nivolumab for Resected Stage III or IV Melanoma at 9 Years
-
Narrated by:
-
Written by:
About this listen
This long-term clinical study evaluates the effectiveness of two different immunotherapy drugs in preventing the return of advanced melanoma following surgical removal. By tracking patients over a nine-year period, researchers demonstrated that nivolumab provides a more durable defense against cancer recurrence compared to ipilimumab. While both treatments showed similar results regarding total lifespan, patients receiving nivolumab experienced fewer distant metastases and required less follow-up systemic therapy. Ultimately, these final findings confirm that nivolumab remains a superior and safer standard for sustaining remission in high-risk skin cancer patients.
No reviews yet